NCT00704054 2015-02-13A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)Merck Sharp & Dohme LLCPhase 1 Completed15 enrolled